QDENGA dengue vaccine to hit India market in 2027; Dr Reddy’s to sell it

India's first approved dengue vaccine, QDENGA, will launch in the private market by mid-2027. Dr Reddy's Laboratories will distribute and promote the vaccine for individuals aged four to sixty. Takeda will retain rights for public market distribution as a future objective. QDENGA is a two-dose vaccine designed to protect against all four dengue virus serotypes. Dengue cases have significantly increased in India over the past two decades.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dGtOv2Z
via IFTTT

Read More

Health ministry issues advisory against unregulated stem cell therapies, restricts autism treatment to approved clinical trials

The Union health ministry issued an advisory against unregulated stem cell therapies. Therapeutic use of stem cells for autism is restricted to approved clinical trials. This advisory reiterates the existing framework governing stem cell research and therapy. It aligns with a Supreme Court ruling restricting unproven stem cell treatments. States and union territories must ensure strict compliance with the applicable framework.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/invwzoN
via IFTTT

Read More

Can wearable tech ease period pain? Curapod launches new device

Curapod has launched a new wearable device for menstrual pain management. This device utilizes red and near-infrared light wavelengths for pain relief. The wearable connects to a mobile application for personalized light dosage adjustments. Clinical evaluations indicate significant pain reduction for many users. The company is expanding its wearable technology into other pain management areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZYaf8nh
via IFTTT

Read More

Centre seeks NPPA report on high markups in hospital consumables

The Centre has requested a report from the NPPA regarding price discrepancies. Maharashtra FDA flagged significant gaps between trade prices and MRPs for hospital items. A survey revealed markups of over 2,800 percent on certain medical consumables. This situation may revive discussions on trade margin rationalisation for medical devices. The medical device industry supports calls for fair pricing and ethical practices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tIavsxu
via IFTTT

Read More

US names India, China, Pakistan among drug transit, illicit drug-producing nations for FY27

The United States has designated India, China, and Pakistan as major drug producing or transit countries. This presidential determination covers twenty-three nations for fiscal year twenty twenty-seven. Afghanistan, Bolivia, Burma, and Colombia were separately identified for failing counternarcotics obligations. Inclusion on the list considers geographic and economic factors for drug production and transport. This designation does not necessarily reflect current government efforts or US cooperation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UOjoGXe
via IFTTT

Read More

Dr. Reddy's launches nivolumab biosimilar in India

Dr Reddy's Laboratories has taken a significant step in cancer care with the introduction of NIVORZ, a biosimilar of nivolumab. Designed to enhance immune response against a variety of cancers, this new treatment has received approval from the DCGI for twelve specific indications. By making this intravenous therapy available, Dr Reddy's aims to broaden access to affordable, high-quality cancer care options for patients in need.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T2NwOSC
via IFTTT

Read More

Centre proposes easier norms for faster drug rollout

India's government plans to streamline drug approval processes for domestic use. Applicants can now start studies after intimating the drug regulator. Import license processing timelines for new drugs will be halved to forty-five days. This move aims to improve the ease of doing business in the sector. However, certain high-risk drug categories will retain existing stringent requirements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cMTsGlP
via IFTTT

Read More

New TB vaccines expected from 2029 could prevent 7.3 million deaths by 2050, Gavi says

By 2029, new tuberculosis vaccines are expected to save more than seven million lives, emerging as a crucial element for global health improvement. Ensuring a steady supply for the countries most affected by the disease is essential. Additionally, these vaccines may provide considerable economic advantages for developing nations. Gavi aims to promote timely accessibility and widespread distribution of these immunizations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y8JHTRa
via IFTTT

Read More

Ayurveda eyes global growth as research, innovation reshape traditional system

Ayurveda is gaining global relevance through research and innovation. Growing interest in holistic healthcare creates new international opportunities for this system. India's Ayush market has seen significant economic growth in recent years. The government promotes Ayush-based medical travel and introduced a dedicated visa. Ayurveda's future international success depends on evidence and standardized practices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/irgcVF9
via IFTTT

Read More

Manipal Hospitals scouts for acquisitions in Andhra, Keralam, Delhi-NCR; bets on AI-led healthcare

Manipal Health Enterprises plans significant expansion across several Indian states. The company is adopting a digital-physical healthcare model driven by Artificial Intelligence. Strategic acquisitions and a new greenfield project in Mumbai are underway. Investments focus on AI-enabled nursing and patient monitoring systems. The healthcare major aims to add over 2,400 beds by the year 2030.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ALijwlZ
via IFTTT

Read More

AstraZeneca's breast cancer drug fails in late-stage trial

AstraZeneca's breast cancer drug Etcamah did not meet its main goal in a late-stage trial. The drug showed only a numerical improvement when combined with palbociclib. This marks a setback for the recently approved treatment, which received accelerated approval. U.S.-listed shares of AstraZeneca experienced a decline in aftermarket trading. Trial data will be shared by the company in due course.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mdZjpwy
via IFTTT

Read More

Imported dialysis solution fails endotoxin test in Himachal; lab flags nine regulatory violations

A Himachal Pradesh government drug laboratory has declared two batches of an imported peritoneal dialysis solution “Not of Standard Quality” after they failed bacterial endotoxin tests. The report also flagged nine regulatory violations, including use of non-Indian pharmacopoeial standards, labelling deficiencies, missing safety warnings and inadequate importer details.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fbDLdI7
via IFTTT

Read More

Alembic Pharma clears USFDA inspection at Vadodara bioequivalence facility with nil observations

Alembic Pharmaceuticals has reported that its Vadodara facility passed the recent inspection by the United States Food and Drug Administration with flying colors. Conducted from August 31 to September 10, 2026, the inspection resulted in zero observations, leading to a clean report from the USFDA and highlighting the facility's commitment to excellence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/a6w7jzn
via IFTTT

Read More

India crosses 80 lakh HPV vaccinations in nationwide cervical cancer prevention drive

India has now administered over 80 lakh HPV vaccinations to girls. This significant milestone strengthens preventive healthcare and protection against HPV infection. The nationwide campaign, launched in February, targets fourteen-year-old girls for free vaccination. The Gardasil-4 vaccine is available at government health facilities across the country. Parental consent is mandatory for this voluntary immunization program.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FGjfMd7
via IFTTT

Read More

Marengo Asia Hospitals raises Rs 400 crore from LeapFrog Investments

Marengo Asia Hospitals has secured Rs. 400 crore funding from LeapFrog Investments. This capital will fuel expansion into tier one and two Indian cities. The company plans to double its hospital bed capacity to 4,000 beds. Marengo Asia Hospitals aims to consolidate its leadership and enter new geographies. This investment reinforces LeapFrog's commitment to healthcare platforms across Asia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HnosAqO
via IFTTT

Read More

iKure bags USD 1.8 Million from global investors to expand primary healthcare in India

iKure Techsoft has successfully raised USD 1.8 million in Pre-Series A funding. This infusion of capital is set to bolster its frontline healthcare workforce and enhance infrastructure, while also advancing its digital health platform through AI integration. iKure aims to provide ongoing care to patients, ensuring access to vital healthcare services for underserved communities across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9XYpLUM
via IFTTT

Read More

Regional healthcare hubs emerge as new investment hotspots

Investment is shifting to regional hospital hubs like Jaipur and Vadodara. These markets offer growth opportunities and lower operating costs for investors. Health insurance penetration is also increasing significantly in these areas. Single-specialty segments like IVF and mother-child care are driving deal activity. Regional hospital brands are expected to scale through clusters and strengthen networks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Dr5QALi
via IFTTT

Read More

WHO chief meets JP Nadda, praises India's health gains in maternal, child care and TB fight

WHO chief Tedros Adhanom Ghebreyesus praised India's health sector progress. He highlighted advancements in maternal and child health initiatives. India's Ayushman Arogya Mandirs bring health screenings closer to communities. ASHA workers support mothers and children from conception through adolescence. Discussions also covered India's efforts to end tuberculosis and strengthen regulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xF7adih
via IFTTT

Read More

Sun Pharma incorporates global treasury arm at IFSC, GIFT City

On September 8, 2026, Sun Pharmaceutical Industries Ltd announced the establishment of its new subsidiary, Sun Pharma Global Treasury Centre IFSC Ltd. Located in Gujarat's GIFT City, Gandhinagar, this wholly-owned indirect unit has seen an investment of around Rs 9.50 crore in its equity share capital. The company is currently awaiting necessary approvals from the International Financial Services Centres Authority to commence its operations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ENqUfp3
via IFTTT

Read More

Tylenol use in pregnancy may be linked with uterus, ovary changes in daughters

A recent study suggests Tylenol use by mothers during pregnancy may affect infant reproductive organ development. Researchers observed smaller ovaries and uteruses in three-month-old girls exposed to the drug. This exposure was also linked to fewer ovarian follicles and lower reproductive hormone levels. Long-term follow-up is needed to determine implications for future fertility and menopause timing. Current guidelines still recommend Tylenol as safe for pregnancy pain and fever relief.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RqiEfv6
via IFTTT

Read More

Government panel plans to retain rule allowing doorstep drug delivery

A government sub-committee has decided to uphold the 2020 rule for doorstep delivery of medicines, recognizing its critical importance for elderly patients and those living in remote locations. Despite the chemists' request to revoke the rule due to concerns of misuse by digital platforms, the sub-committee concluded that maintaining this service is essential for vulnerable populations, recommending instead a stricter enforcement of the existing regulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Jzdx9C8
via IFTTT

Read More

Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid

Rating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries. This action follows Sun Pharma's proposed acquisition of US-based Organon & Co. The deal is expected to significantly bolster Sun Pharma's business position and revenue base. Organon will contribute substantially to the group's earnings after the acquisition. This strategic move will enhance Sun Pharma's scale and geographic reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mpojfhz
via IFTTT

Read More

Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drug

In a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its collaboration with Bahiafarma and Bionovis. This partnership offers exclusive rights to supply the public healthcare sector in Brazil, with plans for phased localization of production. This endeavor aims to improve accessibility to critical cancer therapies while fostering local industry growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/75cGBLe
via IFTTT

Read More

Centre may provide 100% funding support for medical testing equipment, says Piyush Goyal

The government will fully fund the acquisition of advanced medical testing equipment. Domestic firms are encouraged to seek technology partnerships and joint ventures. India aims to become a global hub for medical innovation and device development. Hospitals must offer transparent treatment packages and ethical patient care practices. Enhancing interpreter services will improve foreign patient confidence and communication.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zIGLUJt
via IFTTT

Read More

Novartis India to acquire Pfizer's 'Minipress' trademark for Rs 1,250 crore

Novartis India will acquire the Minipress and Minipres trademarks and related intellectual property from Pfizer for about ₹1,250 crore. Minipress XL, used for hypertension and benign prostatic hyperplasia, generated ₹228.6 crore in revenue as of July 2026, according to IQVIA data.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TNo8DCW
via IFTTT

Read More

'No fake Abhayrab vaccine exported': Indian Immunologicals clarifies after Delhi Police seize counterfeit rabies vaccine batch

Indian Immunologicals confirmed no counterfeit Abhayrab vaccine batch was exported. Four individuals were arrested by Delhi Police after seizing fake vaccine vials. The manufacturer stated all vaccine batches undergo independent testing and government certification. This ensures vaccines reach patients through regulated and authorized supply chains. Previous counterfeit batches had triggered international health authority alerts for travelers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/njKqvM9
via IFTTT

Read More

Pharma sector must attract more investment in clinical trials, R&D: Piyush Goyal

Piyush Goyal emphasized the importance of enhancing India's pharmaceutical industry to draw in more investments. He urged for the creation of robust supply chains to avoid reliance on a single country. The minister also championed the idea of bolstering research and development, securing patents for Indian innovations, and promoting alignment with global regulatory standards. Furthermore, he recommended increasing production in the Ayush sector and medical devices to achieve global recognition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uSMw7cZ
via IFTTT

Read More

Growing peptide trend raises safety concerns among doctors

Doctors express concern over popular injectable peptides for various health benefits. They caution that established peptide medicines differ from experimental compounds promoted online. Social media influencers and wellness trends encourage experimentation with unapproved injectable peptides. Experts emphasize that "peptide" is a chemical category, not a safety guarantee.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VH5JXIE
via IFTTT

Read More

RPG Life Sciences to deploy Rs 500 crore in next 12 months to bolster manufacturing, API capabilities

RPG Life Sciences plans to deploy Rs 500 crore over the next 12 months to expand manufacturing and API capabilities through strategic acquisitions, Managing Director Ashok Nair said. The drugmaker has committed Rs 700 crore for expansion and targets Rs 2,000-2,500 crore revenue by 2030, supported by domestic and international growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JQC9k2U
via IFTTT

Read More

Novartis India to pursue therapy-aligned acquisitions; eyes expansion in Tier 2 and Tier 3 markets

Novartis India plans acquisitions and deeper market penetration for future growth. The company will focus on five key therapy areas for expansion. Established brands will be brought under full commercial control by 2026-27. Rising chronic diseases and an aging population drive sustained therapy demand. Improved insurance and healthcare infrastructure will unlock new patient demand.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lN0ugx3
via IFTTT

Read More

Seized Abhayrab vials not manufactured by company: Indian Immunologicals Limited

Indian Immunologicals Limited has asserted that the rabies vaccine vials in question were not produced by their facility. Following a potency test failure, a batch was labeled substandard by the drug regulator. IIL emphasized that the Central Drugs Laboratory in Kasauli had assessed and approved the batch. The company identified seventeen discrepancies between the seized vials and their retention samples.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LFCcRA5
via IFTTT

Read More

Govt flags Abhayrab rabies vaccine batch as substandard, probes if spurious, document shows

India's drug regulator has flagged a batch of Abhayrab rabies vaccine as substandard. This finding marks the second time concerns have been raised about counterfeit Abhayrab doses. The government's Central Drugs Laboratory found the vaccine did not meet potency requirements. Significant differences were noted between the sampled product and a reference sample. The regulator is investigating whether the vaccine is spurious under Indian law.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WJKZFAz
via IFTTT

Read More

Moopen family picks up additional stake in Aster DM Quality Care for Rs 350 cr

Union (Mauritius) Holdings acquired a 0.57 percent stake for Rs 350.34 crore. This acquisition increased the Moopen family's total shareholding to approximately 24.58 percent. The transaction involved purchasing equity shares from Centella Mauritius Holdings Ltd. The deal was executed at a price of Rs 760 per share on September 2. Aster DM Quality Care now operates a network of 39 hospitals across 28 cities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j6mh1zy
via IFTTT

Read More

Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar

Cipla said its US unit has entered an exclusive partnership with China’s Qilu Pharmaceutical to license QL2107, a biosimilar of Merck’s cancer drug Keytruda. Qilu will handle development, approvals, manufacturing and supply, while Cipla USA will commercialise the treatment in the US, as Cipla expands its oncology biosimilars portfolio.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TJnt7ON
via IFTTT

Read More

Drug cos refuse to take sole responsibility for overpricing

Indian drugmakers oppose a proposal making them solely liable for medicine overpricing. This regulatory move exempts retail chemists, hospitals, and nursing homes from penalties. Pharmaceutical groups argue this unfairly burdens manufacturers already following pricing rules. Retail chemists, however, welcome the safeguards for their members. Manufacturers believe accountability should extend to those setting the final patient price.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A9slboD
via IFTTT

Read More

Cohance Lifesciences to invest USD 18 mn in NJ Bio, Aruka Bio

Cohance Lifesciences announced an eighteen million dollar investment to strengthen its antibody-drug conjugate strategy. This includes thirteen million dollars for NJ Bio, increasing Cohance's ownership to sixty-seven point three percent. An additional five million dollars will give Cohance a sixty-five percent stake in Aruka Bio. These transactions aim to integrate NJ Bio's services with Cohance's manufacturing capabilities. Completion of these strategic investments is expected by September twenty twenty-six.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j7mLd9n
via IFTTT

Read More

Max Healthcare to invest Rs 6,200 cr to reach 10,000-bed capacity in 3 years: CMD

Max Healthcare plans to expand its bed capacity to ten thousand beds. This significant expansion will involve an investment of approximately six thousand two hundred crore rupees. The company's growth is driven by increasing domestic demand and India's medical tourism prominence. Medical tourism currently represents nine percent of the company's overall business operations. This strategic move aims to address the growing healthcare needs across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4a5D6lo
via IFTTT

Read More

RPG Life Sciences subsidiary acquires Raghava Life Sciences' API biz for Rs 135 cr

RPG Active Pharma is acquiring Raghava Life Sciences' API and intermediates business. This strategic move aims to strengthen its integrated API play and manufacturing footprint. The acquisition includes twenty-two commercialized APIs and seven development-stage assets. This transaction will be executed on a going-concern basis through a slump sale.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OgsZw8E
via IFTTT

Read More

Monsoon illnesses & flu surge lift drug demand

Monsoon illnesses and a significant rise in H1N1 cases are driving a surge in demand for acute therapies and flu vaccines. Sales of anti-infectives and antibacterials saw a 12% month-on-month increase in July, with flu vaccine sales nearly tripling year-on-year in August, leading to supply challenges in several cities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ak4YGcN
via IFTTT

Read More

Sun Pharma agrees to lower US drug prices under Trump plan; analysts see limited financial impact

Sun Pharmaceutical Industries will offer its drugs at prices matching other developed nations. This agreement aims to make healthcare affordable for low-income Americans. Analysts believe the financial impact on Sun Pharma will be minimal. The company's US revenue contribution is significant, reinforcing its growth strategy. This pact recognizes Sun Pharma's investment in the American market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/72ErY3T
via IFTTT

Read More

Permira to buy 25.71% in Cloudnine Hospitals parent: CCI filing

Permira, a leading global private equity firm, is ready to buy a significant stake in Cloudnine Hospitals, which places the parent company's valuation at approximately eleven thousand crore rupees. This acquisition involves purchasing the stake from existing investor True North Capital. The deal awaits appropriate regulatory clearances, and Cloudnine is also exploring acquisitions of further hospital ventures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gIk8GKT
via IFTTT

Read More

Sun Pharma to extend MFN pricing to US state Medicaid programmes

Sun Pharma ranks second in US dermatology by prescriptions, with key brands including Ilumya for plaque psoriasis and Winlevi for acne. Recent US launches include Leqselvi for severe alopecia areata and Unloxcyt for advanced cutaneous squamous cell carcinoma, strengthening its presence in dermatology and cutaneous oncology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4aMSKxO
via IFTTT

Read More

Delhi HC orders forensic audit of Fortis, Singh brothers' Rs 4,666-crore trail

The Delhi High Court ordered a forensic audit of Fortis Healthcare transactions. This audit will examine dealings with IHH Healthcare Berhad and RHT Health Trust. It will also probe transactions involving the Singh brothers and Religare Group companies. The court seeks to trace the movement of shares and funds. This comprehensive audit must be completed within six months.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QbyhGro
via IFTTT

Read More

Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump says

Nine pharmaceutical firms reached deals with the Trump administration for lower drug prices. These agreements expand the total number of companies to twenty-six manufacturers. The deals cover medicines for chronic and rare diseases, benefiting Medicaid programs. Sun Pharma will contribute antibiotics to the US Strategic Active Pharmaceutical Ingredients Reserve. These initiatives aim to reduce reliance on foreign suppliers and lower costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WK9DlJh
via IFTTT

Read More

Zydus’ Saroglitazar meets primary goal in global Phase II(b) MASH trial

Zydus Lifesciences said its drug Saroglitazar Magnesium met the primary goal of a global Phase II(b) trial for MASH, a serious liver disease linked to metabolic disorders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/a6rsDj4
via IFTTT

Read More

India seeks easier pharma access in Brazil, pushes to expand Mercosur trade pact

India seeks predictable regulations and easier market access for its pharmaceutical products. Discussions occurred at the India-Brazil Trade Monitoring Mechanism meeting in Brasilia. Both nations aim to expand the existing India-Mercosur trade agreement soon. Bilateral trade between India and Brazil is targeted to reach thirty billion dollars. This move aims to deepen economic ties and expand India's Latin American market presence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/61n5FEv
via IFTTT

Read More

Healthcare ranks second in private credit deals as domestic funds dominate in H1 2026: EY report

India’s private credit market deployed $3.5 billion across more than 100 deals in H1 2026, broadly unchanged from $3.4 billion in H2 2025, according to EY.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QVWef32
via IFTTT

Read More

Jharkhand on high alert over Swine Flu; Health Minister directs hospitals to reserve beds, ramp up surveillance

Jharkhand Health Department is on high alert for potential H1N1 cases. Health Minister Irfan Ansari directed enhanced surveillance and hospital preparedness across the state. Ten additional beds are reserved in all medical college and district hospitals. Monitoring of Influenza-Like Illness and Severe Acute Respiratory Infection cases is intensified. Health teams will screen individuals at major transit points for immediate care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EIXoHG0
via IFTTT

Read More

Park Medi World to expand hospital network across north India, add 1,450 beds by FY28

Park Medi World plans to add 1,450 beds by FY28, expanding its northern India network. The hospital chain focuses on Tier 1, 2, and 3 cities for efficient scaling. Acquisitions will target hospitals with 200-250 beds, expandable to 350. The company reported record net profit and revenue in FY26. Park Medi World is also adopting cleaner energy systems across its facilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/M7wtTK1
via IFTTT

Read More

Amrutanjan Health plans to set up 1 lakh direct chemist outlets in FY27

Amrutanjan Health Care plans to establish one lakh direct chemist outlets this fiscal year. The company achieved strong growth in pain management and women's hygiene categories during FY26. This expansion aims to increase brand availability beyond its traditional strongholds in the south and east. Amrutanjan also intends to relaunch its congestion-relief brand, Relief, in the current year. The company remains confident about demand in FY27, supported by its product portfolio.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iVRtT8w
via IFTTT

Read More

Is longevity the new flex? Why the new wellness status game is all about health data

Wellness has shifted from luxury retreats to daily personal management and longevity. Wearable technology now tracks health markers, encouraging consistent self-care habits. Fitness goals are increasingly performance-driven, moving beyond aesthetics and appearance. Nervous system regulation through breathwork and sound baths is gaining prominence. This new focus emphasizes consistent, unglamorous daily habits for long-term health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DMfNSWG
via IFTTT

Read More

Cipla Pharma license cancellation: FDA withdraws order after HC raps it for going 'overboard'

Maharashtra FDA withdrew its order to cancel Cipla Pharma's drug sale license after court intervention. The Bombay High Court criticized the regulator for acting in a high-handed and overboard manner. The FDA will now issue a fresh show cause notice to the company for a reasoned order. This action followed alleged irregularities in packaging, storage, and recall of specific tablets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8RsXVBK
via IFTTT

Read More

Drugmakers may bear sole responsibility for overpricing essential medicines under NPPA proposal

The National Pharmaceutical Pricing Authority aims to hold drug manufacturers solely accountable for the excessive pricing of essential medications. This initiative could shield retail chemists and hospitals from legal repercussions concerning pricing infractions. Manufacturers are likely to challenge the proposal, alleging it is uncompromising and unjust. Previously, substantial penalties have been levied against drugmakers for such transgressions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Jwgi9SV
via IFTTT

Read More

Jubilant Generics receives show-cause notice demanding over Rs 105 cr

Jubilant Generics received a Rs 105.5 crore GST show-cause notice from Uttarakhand authorities. The notice alleges improper availment of tax refund and Advance Authorisation Scheme benefits. This action pertains to the fiscal years 2020-21 and 2021-22. The company plans to contest the notice and file a detailed reply soon. Jubilant Pharmova expects no significant financial or operational impact.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/m9k6XZl
via IFTTT

Read More

Yatharth Hospitals draws interest from Aster, Advent as healthcare consolidation heats up

Aster DM Quality Care is negotiating to acquire a controlling stake in Yatharth Hospitals. This potential acquisition aims to consolidate the hospital sector amid private equity interest. Yatharth Hospitals' stock has seen a significant rise in anticipation of a potential trade. The deal would trigger an open offer for additional shares, expanding the acquirer's ownership. This move would significantly strengthen Aster DM Quality Care's presence in northern India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Kn6AYql
via IFTTT

Read More

Demand for vaccines surges as H1N1, other influenza cases see a sharp rise

Demand for flu vaccines has significantly increased this year. At-home vaccination services are seeing a substantial rise in bookings. Rapid testing requests are also growing from various Indian cities. This surge is driven by elevated viral spread and increased awareness. Experts recommend annual vaccinations and usual protective measures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JLdDf1V
via IFTTT

Read More

Convening India's brightest minds: The Bharat Life Sciences Award’s Innovation Summit to spotlight life sciences

India sets its sights on becoming a frontrunner in innovation within the life sciences arena. The Bharat Life Sciences Award 2026 aims to honor exceptional scientific achievements while promoting teamwork. With leaders gathering to enhance manufacturing and drug discovery capabilities, discussions will delve into topics like AI-driven discovery and cutting-edge vaccine technologies, ultimately aiming to define the future of India's life sciences landscape.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sDSRyfQ
via IFTTT

Read More

Piramal Alternatives invests Rs 215 crore in Kolors Healthcare

Kolors plans to use the latest capital infusion to strengthen its regional footprint while expanding into additional segments of the wellness and preventive healthcare market. The company also plans to implement its "Kolors 2.0" initiative, which involves a broader transformation of its centres and operations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/C3n1Nld
via IFTTT

Read More

Kedaara pumps $200m into ortho support wear maker Tynor

Kedaara Capital has acquired a majority stake in Tynor Orthotics for approximately $200 million. This significant deal provides an exit for investor Lighthouse Funds from the medical device maker. Tynor Orthotics manufactures orthopaedic supports and mobility aids for global markets. The company has an extensive distribution network reaching numerous retail outlets and hospitals. Kedaara will partner with Tynor's promoters and its existing strategic partner Thuasne.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c3aRA2F
via IFTTT

Read More

Grip strength, gait may soon measure biological lifespan, says Dr Prateek Sharma

Genes influence lifespan, but lifestyle and environment are crucial for longevity. Biological age will soon be measured by new indicators beyond chronological age. Healthy life expectancy boosts India's economy significantly, benefiting all stakeholders. The focus is shifting from lifespan to healthspan, adding energy and reducing disease. Evidence-based nutrition science is vital, dispelling myths about magic diets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wZ3IEiA
via IFTTT

Read More

Kedaara Capital bets on India’s orthopaedic market with $200 million Tynor deal

Kedaara Capital has acquired a majority stake in Tynor Orthotics for $200 million. This private equity firm is expanding its medical devices portfolio with this significant investment. Tynor Orthotics is a leading Indian manufacturer of orthopaedic and rehabilitation products. The company has a wide distribution network reaching many countries globally. Kedaara will partner with existing promoters and management to drive future growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sWElm3B
via IFTTT

Read More

Biocon arm gets Japan nod for cancer drug pegfilgrastim biosimilar

In a significant advancement, Biocon Biologics has gained marketing approval for its pegfilgrastim biosimilar in Japan. This vital cancer supportive care drug is designed to mitigate infection risks following chemotherapy. Developed as a rival to Neulasta, Sandoz KK will handle its exclusive promotion and distribution. This approval marks a pivotal step in expanding Biocon's biosimilar range and improving patient accessibility worldwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aHGz7cR
via IFTTT

Read More

Govt eases loan licence requirement for 'outsourced' sterilisation of medical gear

Medical device makers now avoid loan licenses for outsourced sterilization services. This change simplifies business while industry leaders express concerns about new labeling rules. Printing sterilizer license numbers on device labels may hinder export flexibility and cause shipment delays. Manufacturers worry about losing the ability to choose the fastest available sterilization facility. The government also recognized the European Union for clinical investigation waivers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gTqpi32
via IFTTT

Read More

DRL, Emcure get approval to make breakthrough HIV drug

India's drug regulator has cleared the path for local lenacapavir manufacturing. Two Indian pharmaceutical companies received waivers for local clinical trials. This move will improve access to the HIV prevention injection. Lenacapavir is a breakthrough twice-yearly injection for HIV prevention. Patient groups had urged the regulator to expedite this process.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uDHPmRf
via IFTTT

Read More

Adani Group to set up 2,000-bed hospital in Bengal, 1,000 beds to be free

The Adani Group plans to establish a significant 2,000-bed hospital in New Town. Half of these beds will be allocated for free treatment of the poor. West Bengal Chief Minister Suvendu Adhikari confirmed this development. He stated that Karan Adani had met him regarding the project. Gautam Adani has sent a commitment letter to begin work soon.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fwDN7Sk
via IFTTT

Read More

USFDA ends inspection of Aurobindo Pharma arm's facility with 4 observations

Aurobindo Pharma announced its subsidiary Lannett Company LLC's facility inspection concluded. The US Food and Drug Administration conducted this routine inspection from August 17-21, 2026. Four procedural observations were noted during the Seymour, USA facility's review. The company will provide its response to the USFDA within the required timeframe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vwhXlj3
via IFTTT

Read More

Indian pharma has little reason to fear Trump

US tariff threats on Indian generic drugs face significant obstacles. These duties could increase American healthcare costs and potentially cause shortages. Indian firms operate on low margins, making tariff absorption difficult. Recent US manufacturing experiences offer little incentive for relocation. Targeted incentives offer a more direct approach to supply chain resilience.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5tyzLi0
via IFTTT

Read More

Udan vs Udaan: Delhi court restrains pharmaceutical firm from using 'Udaan' mark

A Delhi court has permanently stopped Sainus Pharmaceutical Private Limited from using the 'Udaan' trademark. This ruling came after RSPL Health Private Limited filed a case alleging trademark infringement. RSPL Health, known for its 'Ghari' detergent brand, had registered its 'Udan' mark earlier. The court found Sainus Pharma's mark to be identical and deceptively similar to RSPL's registered trademark.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hBDI0m6
via IFTTT

Read More

Govt tightens rules on combinations containing 2 chemical compounds for young children

The government has restricted fixed-dose combinations containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride. These medicines are now prohibited for use in children below four years of age. Manufacturers must clearly display a warning on all associated product packaging. This action follows recommendations from an expert committee and the Drugs Technical Advisory Board. The notification is effective from its publication date in the official gazette.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g6Cole3
via IFTTT

Read More

Zydus Lifesciences gets USFDA nod for generic ascorbic acid injection

Zydus Lifesciences secured final USFDA approval for its generic ascorbic acid injection. This approval is for the treatment of scurvy in specific patient groups. The company's product is the generic equivalent of the Ascor injection. The USFDA designated this application as a Competitive Generic Therapy. Zydus will market the product in the United States market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/m7sBK6b
via IFTTT

Read More

Medical devices industry needs to focus more on local value addition: Pharma Secy

The medical devices sector must increase local value addition and component manufacturing. Government officials are open to industry suggestions for PLI scheme beneficiaries. Many companies invested but could not claim incentives for various reasons. The government aims to incentivize component makers more than assembly operations. Increased domestic value addition is a key objective for the sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O5IK8kP
via IFTTT

Read More

Delhi High Court rules in favour of Dr Reddy's Labs in trademark row with Razenta

The Delhi High Court ordered the removal of Razenta Pharmaceuticals' Daplogin trademark. This decision came as the mark was deemed deceptively similar to Dr Reddy's Labs' Daplo trademark. Both trademarks are used for prescription drugs treating Type-2 diabetes Mellitus. The court cited phonetic similarity and potential consumer confusion as key reasons. Razenta's trademark registration was cancelled within six weeks by the court.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bBO9zsi
via IFTTT

Read More

Lupin arm to commercialise YUVEZZI eye drop across key European markets

Lupin's VISUfarma BV has secured exclusive rights for YUVEZZI in key European markets. This ophthalmic product treats loss of clear close-up vision in adults. VISUfarma will undertake regulatory activities and commercialization of the eye drop. The agreement includes a strategic investment and potential milestone payments. YUVEZZI represents a significant advancement in eye care for presbyopia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bm03Nq4
via IFTTT

Read More

Moderna, Merck breakthrough could usher in wave of cancer vaccines

Merck and Moderna's personalized cancer vaccine shows promise for melanoma patients. This new treatment trains the immune system to target specific tumor mutations. The vaccine, combined with Keytruda, significantly reduced cancer recurrence in trials. Doctors are hopeful this approach will expand to treat many other cancer types. Further trials are underway for lung, bladder, kidney, pancreatic, and stomach cancers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p51oUgc
via IFTTT

Read More

Pharma giant Cipla completes merger with wholly-owned subsidiary Inzpera Health Sciences

Pharmaceuticals giant Cipla announced its merger with Inzpera Healthsciences Limited on Wednesday. This consolidation aims for more efficient resource utilisation and greater economies of scale. The merger will improve operating parameters and maximise shareholder value through integration. Greater efficiency in cash management and access to cash flows is also expected. Business processes will be simplified, reducing administrative expenses and compliance costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CBf5Zeo
via IFTTT

Read More

Lord’s Mark Industries announces license for biomescan analytics platform

Lord's Mark Industries has obtained a license for its groundbreaking Biomescan Analytics Platform, which specializes in assessing the gut microbiome to deliver customized health insights. With ambitious plans to set up 3,000 health centers across India in the next three years, the initiative aims to offer gut assessments and personalized nutritional advice, promoting proactive health and enhancing long-term wellness outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xolc8ZJ
via IFTTT

Read More

Apollo Hospitals extends services to all seven days of week

Apollo Hospitals will now offer routine healthcare services on Sundays. This initiative extends outpatient consultations and diagnostic services to weekends. Scheduled procedures and follow-up care will also be available, complementing existing emergency services. The hospital group aims to improve access for busy professionals and families. This move reinforces Apollo's commitment to preventive and timely medical care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BYSO56a
via IFTTT

Read More

Manipal Health Enterprises to acquire Kinder Women's Hospital in Bengaluru

Manipal Health Enterprises will acquire Kinder Women's Hospital in Bengaluru for Rs 130 crore. This business transfer agreement involves acquiring the hospital's entire operations and assets. The acquisition strengthens Manipal Hospitals' position in a growing Bengaluru healthcare market. It will also expand access to their clinical expertise and capabilities for more patients. This move complements their existing healthcare ecosystem in the Whitefield micro-market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YGcSIrw
via IFTTT

Read More

Healthcare delivery capital-intensive, hospital tariffs only tip of iceberg: NATHEALTH

Healthcare delivery costs are capital-intensive and investment-heavy, according to NATHEALTH. Policy discussions should address structural costs like land and manpower. Hospitals require continuous investment in infrastructure and specialized equipment. The industry warns against regulatory changes that deter expansion and innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2IDifRN
via IFTTT

Read More

India's pharma sector must shift from cost competitiveness to innovation, global quality: Experts

For the growth of India's pharmaceutical sector, prioritizing innovation and advanced manufacturing is essential. Experts indicate that increasing investments in research and digital technologies could propel the market to an impressive USD 130 billion by 2030. Companies must also elevate their quality and comply with global regulatory expectations to compete in the global landscape, thus establishing India as an innovation hub in life sciences.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ILvMO8R
via IFTTT

Read More

Lupin gets USFDA nod for generic tablets to treat excessive daytime sleepiness

Pharma major Lupin Ltd announced receiving final USFDA approval for its generic Pitolisant tablets. These tablets are indicated for treating excessive daytime sleepiness in patients. The US health regulator approved strengths of 4.45 mg and 17.8 mg. Lupin's Pitolisant tablets are bioequivalent to Wakix, a prescription medicine. This approval marks a significant step for the company in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EmgD0VJ
via IFTTT

Read More

Aurobindo Pharma’s Raleigh plant gets 'Voluntary Action Indicated' classification from US FDA

Aurobindo Pharma's US facility received a Voluntary Action Indicated classification. The US FDA closed its inspection of the Raleigh manufacturing plant. This classification allows applications for inhalers and other products to proceed. The inspection covered inhaler, dermatology, and transdermal product manufacturing operations. The company's regulatory filing confirmed the inspection closure and VAI status.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0Vnv42K
via IFTTT

Read More

India plans national sports medicine framework ahead of 2036 Olympics

India plans a national sports medicine framework for preventive athlete care. This initiative aims to standardize injury protocols and link medical institutions. The government considers a phased rollout by 2028 for this new system. This framework will improve athlete availability and long-term career sustainability. The proposal supports India's potential 2036 Olympic Games bid.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7stunQp
via IFTTT

Read More

In private healthcare's rise, price points are a big pain

In a recent proposal, a parliamentary committee has recommended that hospital room charges not exceed the rates of three-star hotels. The substantial growth of private healthcare as an industry has attracted considerable private equity investment, resulting in valuation spikes and shifts in ownership among hospital chains. However, this raises important questions about the accessibility of healthcare for the average person.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UQe6Rc9
via IFTTT

Read More

AI could cut doctors' paperwork burden as global health worker shortage looms: Report

Artificial intelligence can ease doctor workloads by handling repetitive administrative tasks. This technology helps address a growing global healthcare worker shortage. AI tools can draft clinical documentation, freeing up valuable physician time. Patients can also benefit as AI helps direct them to appropriate care. Ultimately, AI aims to optimize existing healthcare staff for future demands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ci0UH8Y
via IFTTT

Read More

Thermo Fisher finds India the perfect lab; lab equipment maker steps up investments as drug companies focus on innovation

Thermo Fisher Scientific is amplifying its investment footprint in India, driven by the strong anticipated growth in the biosimilars and innovative medicines sectors. With projections indicating a substantial rise in India's biosimilars exports by 2030, local pharmaceutical companies are pivoting towards advanced biologics and research initiatives. To foster scientific talent, Thermo Fisher has also established a bioprocess center in Hyderabad for comprehensive training.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TPJej1A
via IFTTT

Read More

Aurobindo Pharma arm Eugia Pharma's Telangana unit gets warning letter from USFDA

Aurobindo Pharma announced its subsidiary Eugia Pharma received a USFDA warning letter. This follows an inspection of their Telangana formulation manufacturing facility. The inspection concluded with four observations and an official action indicated status. The company stated existing US market supplies remain unaffected by this development. Aurobindo Pharma continues its commitment to ongoing compliance with the US FDA.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ftbaj2p
via IFTTT

Read More

Gland Pharma appoints Dr Reddy’s senior executive Deepak Sapra as CEO

Gland Pharma has appointed Deepak Sapra as its new chief executive officer, with his tenure set to begin on November 16, 2026, subject to his acceptance of the offer. Sapra brings 27 years of executive experience, including over 23 years in pharmaceuticals, and currently leads API and Services at Dr Reddy’s Laboratories.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5hNoz4M
via IFTTT

Read More

Delhi HC backs Zydus in trademark row

The Delhi High Court upheld a single-judge order against Alder Biochem. This ruling prevents them from using the 'Biochem' trademark. Alder Biochem's claim of the term being public property was rejected. Zydus Healthcare has held the registered trademark since 1959. The court's decision protects Zydus Healthcare's established brand.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gW8LpqF
via IFTTT

Read More

Narayana Health, NDB sign pact to share smart hospital expertise

Narayana Health and the New Development Bank have signed a knowledge-sharing agreement. This partnership aims to strengthen smart hospital capabilities and patient-centric healthcare services. The collaboration will focus on digital health and technology transfer for emerging economies. NDB president Dilma Rousseff and Narayana Health chairman Dr Devi Shetty signed the memorandum. This initiative supports NDB's mission to finance development projects in emerging markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6KRl4BX
via IFTTT

Read More

Govt tightens drug quality net, initiates 950 actions since 2022: Over 1,100 cough syrup makers are also facing intensive audits amid quality concerns

The government has initiated 950 enforcement actions against pharmaceutical companies since December 2022. These actions aim to improve the quality of locally made medicines and prevent spurious drug sales. More than 1,100 cough syrup manufacturers are facing intense audits due to quality concerns. Drug manufacturing premises are inspected periodically to verify compliance with good manufacturing practices. Risk-based inspections are now prioritized based on a company's risk profile.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gSt4ryk
via IFTTT

Read More

Maharashtra FDA cracks down on Ayurvedic drug makers, cancels 10 licences

Maharashtra FDA has launched a statewide crackdown on Ayurvedic drug manufacturers. Inspections revealed serious violations of manufacturing and quality control standards at many establishments. Following these findings, 135 manufacturers received show-cause notices for non-compliance issues. Ten manufacturers had their licenses permanently cancelled due to major violations affecting public health. The FDA is ensuring Ayurvedic medicines meet required standards and addressing public health lapses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DpL0RfQ
via IFTTT

Read More

Regulator mandates full review of globally unapproved drugs

India’s drug regulator has clarified that new drugs not approved anywhere globally must undergo the full domestic regulatory process, even if Indian patients participated in global clinical trials. CDSCO said such applications require comprehensive safety and efficacy evaluation under existing rules.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/t7GwBYO
via IFTTT

Read More

US-based Amgen to open science and innovation center at Genome Valley in Hyderabad

Amgen will open a new science and innovation center in Hyderabad's Genome Valley. This facility is expected to become operational by the year 2027. The center will integrate experimental science with data and technology. It will expand Amgen's global research and development capabilities significantly. This investment highlights Hyderabad's growing importance as a global research hub.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nrjhl6a
via IFTTT

Read More

Philips India sees India emerging as global R&D, AI hub; bets on healthcare infrastructure for growth

Philips India is focusing on growing healthcare infrastructure and artificial intelligence. The company's R&D footprint in India is significantly strengthening its global operations. Investments will continue to support Philips' positive growth story in the country. Philips sees opportunities in sleep and respiratory care as awareness increases. The company prioritizes value over price when facing competition from other firms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sVzXPZ0
via IFTTT

Read More

Doctors' safety alert led to Sun Pharma eye drop recall

Sun Pharma recalled eleven eyecare products after an eye specialists' body issued a safety alert. This alert warned about bacterial contamination found in certain batches of their Predmet eyedrop medicine. The All India Ophthalmological Society stressed patient safety due to potential serious ocular infection risks. Sun Pharma stated the recall was a precautionary measure while investigations continued. The company assured that other products were manufactured at different qualified sites.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZuyJwrL
via IFTTT

Read More

Medical devices are not pharma products, companies say while opposing Draft Bill

India’s medical device industry and healthcare groups have opposed the draft Drugs, Medical Devices and Cosmetics Bill, 2026, arguing that treating medical devices like pharmaceuticals and imposing criminal penalties for regulatory lapses could hurt manufacturing, investment and innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1GpvPLc
via IFTTT

Read More

Wockhardt takes on India’s superbug crisis with new antibiotic academy

Wockhardt has launched the Antibiotic Academy, an open scientific learning platform to strengthen clinical dialogue and evidence-based management of antimicrobial resistance in India. The initiative will connect clinicians, experts, hospitals, scientific societies and policymakers to promote appropriate antibiotic use.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0aSxlTn
via IFTTT

Read More

Warburg set to buy Seacod-maker Universal NutriScience for Rs 2800 crore

Will be 4th acquisition for the US private equity giant in India’s healthsector in four months. Kedaara to make 5x rupee returns on exit.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MZxPlOS
via IFTTT

Read More

Gland Pharma inks strategic CDMO deal with global pharma firm, eyes $90-100 million annual revenue

Gland Pharma has signed a strategic Manufacturing and Supply Agreement with a leading global pharmaceutical company for technology transfer, manufacturing and supply of sterile injectable products. The agreement covers 55 SKUs across three sites, with annualised revenue potential of $90-100 million upon commercialisation. Revenue generation is expected to begin in 2029.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aBfGJPW
via IFTTT

Read More

IIT Guwahati develops 'E-Eye' for rapid detection of Cancer-causing heavy metals and other toxicants

IIT Guwahati researchers have developed an innovative optical sensing device for detecting water toxicants. This portable E-Eye device offers instant and accurate on-site analysis of various contaminants. It works by converting chemical reactions into digital data for easy interpretation. The technology aligns with the Jal Jeevan Mission, aiming to ensure safe drinking water for all. This innovation holds significant potential for government, industry, and public health applications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LCGKXBI
via IFTTT

Read More

Govt plans new drugs law to overhaul pharma, medical device regulation

The government is set to replace the 1940 Drugs and Cosmetics Act with a new law covering drugs, medical devices and cosmetics. The draft bill strengthens the powers of the DCGI, introduces stricter bail provisions for serious drug offences, enables faster approvals and recalls, and creates dedicated regulatory and advisory bodies for medical devices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oAaKHfU
via IFTTT

Read More

Emcure Pharma net profit up 36% at Rs 292 crore

Emcure Pharmaceuticals reported a 23% revenue increase in the first quarter. Ebitda grew 25.8% with improved margins, reflecting productivity gains. Net profit saw a significant 36.2% rise during the period. The company began its five-year plan on a strong footing for FY27. Emcure also completed the acquisition of a minority stake in Gennova Biopharmaceuticals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6Lxt2Mk
via IFTTT

Read More

KKR deepens India healthcare bet with $1.39 billion Medicover acquisition

Global investment firm KKR has acquired Medicover India's hospital network for $1.39 billion. This acquisition marks KKR's third hospital purchase in recent years. Medicover India operates 24 multi-specialty hospitals across South and West India. The European healthcare chain will now focus its operations solely within the continent. This transaction allows Medicover to strengthen its financial position and pursue European growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0zUcEjF
via IFTTT

Read More

Centre to bar drugmakers from selling mislabelled, fraudulently approved products under new provisions

New rules will bar drugmakers from selling products if false information was provided. The Union Ministry of Health & Family Welfare has amended the Drugs Rules, 1945. This adds accountability for drug manufacturers and distributors operating in the country. The Licensing Authority can now debar entities from filing future applications. This amendment aims to deter misconduct and ensure reliable drug approval evidence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/B15tvuK
via IFTTT

Read More

KKR buys Medicover’s India hospitals business

Global investment firm KKR has acquired Medicover India's hospital business. Sources said the the transaction values the hospital chain at around ₹10,000 crore and KKR may invest another ₹3,000-4,000 crore to fuel expansion. The acquisition strengthens KKR's healthcare portfolio, adding Medicover's 24-hospital network while reinforcing its long-term strategy to capitalise on India's rapidly growing healthcare and hospital sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7foyniQ
via IFTTT

Read More

KKR to acquire Medicover India in $1.5 billion deal

The transaction includes a sale of 100% stake by existing shareholders, as well as a commitment to deploy fresh capital to fund its growth and repay debt. In all, KKR will be spending Rs 13,000-14,000 crore, around quarter of which (Rs 3,000-4,000 crore) will go into the company as primary capital, said people aware of developments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7YfatJ9
via IFTTT

Read More

Delhi HC seeks response on Natco's patent challenge plea

The Delhi High Court is reviewing Natco Pharma's challenge to a breast cancer drug patent. Natco alleges Novartis and Astex secured two patents for the same invention. This action, Natco claims, unlawfully extends patent protection for the Ribociclib molecule. The court will first determine the petition's maintainability after legal arguments. The case has been scheduled for further hearing on September 16.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/m8p3J7K
via IFTTT

Read More

Cipla, Rocket India announce Rs 300 crore expansion plans in Karnataka; Blackstone eyes data centres

Cipla and Rocket India will invest Rs 300 crore in Karnataka's manufacturing facilities. Blackstone is exploring investments in data centers and renewable energy infrastructure. Saint-Gobain plans to expand its manufacturing footprint within the state. Horizon is encouraged to consider industrial projects in tier two cities. These announcements occurred during Karnataka's investment roadshow in Mumbai.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W46dIZb
via IFTTT

Read More

IPA seeks to regularise 'legacy' drugs

The Indian Pharmaceutical Alliance seeks to regularize many drugs. These drugs have been marketed for years without central approval. Examples include sodium valproate and carbamazepine tablets. Regulatory gaps have persisted for over a decade. This situation requires urgent attention from drug authorities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vClqPwm
via IFTTT

Read More

Dr Reddy's Laboratories launches generic Sugammadex injection in the United States

Dr Reddy's Laboratories has launched its generic Sugammadex injection in the United States. This new product reverses muscle relaxant effects given during surgical procedures. The company's hospital portfolio expands with this important medicine's availability. Sugammadex injection is a vertically integrated product manufactured through Dr Reddy's global network. This launch occurred on the first day of generic availability in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SiFyJOU
via IFTTT

Read More

India pharma sector to miss 2030 sales target amid tariff and shipping woes, trade body says

India's pharmaceutical industry is expected to reach$80-90 billion by 2030, well below its earlier$130 billion target, as U.S. tariff uncertainty and Middle East shipping disruptions hurt exports, Pharmaceuticals Export Promotion Council of India Chairman Namit Joshi told Reuters.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/867Jmlf
via IFTTT

Read More

Private equity firm Creador in talks to buy into generic drug co Leeford Health

Private equity firm Creador is in advanced talks to acquire a stake. The firm expects to invest ₹800 crore in Leeford Healthcare. This acquisition would value the generic drugmaker at ₹8,000-₹8,500 crore. Leeford Healthcare is a diversified pharmaceutical and wellness company. This deal marks the company's first ownership dilution to an external investor.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Kf5xhTv
via IFTTT

Read More

Two-wheeled road ambulance to run from October 1, 2027

The Centre has proposed introducing a regulatory framework for two-wheeled road ambulances, which will become operational from October 1, 2027, to improve emergency medical access in rural, remote and hilly areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kKeP0ZV
via IFTTT

Read More

Losing weight fast on GLP-1 drugs? Your hair could be the next thing to go

Dermatologists report increased hair loss among GLP-1 drug users experiencing rapid weight reduction. This side effect, often telogen effluvium, stems from nutritional deficiencies and metabolic stress. Many patients start these medications without proper medical supervision, influenced by social media trends. Studies show a high prevalence of hair shedding, particularly among women and significant weight losers. Doctors advise medical supervision and balanced nutrition to manage this temporary condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iSpeEKr
via IFTTT

Read More

India's Second Leapfrog: From sick-care to AI-native health infrastructure

Just as India bypassed copper landlines to become a global mobile data leader, it can now bypass the West's CPT-coded sick-care bureaucracy and build AI-powered, personalised healthspan infrastructure for the world.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VWaiTPn
via IFTTT

Read More

GLP-1 demand stirs up hunger for obesity care talent

Demand for nutrition professionals is rapidly increasing across India. Hospitals and digital health platforms are hiring more dietitians and educators. This trend supports patients using new GLP-1 obesity medications. Specialized obesity care teams are expanding to meet growing patient needs. Long-term monitoring and lifestyle support are crucial for sustained health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7SEy0he
via IFTTT

Read More

Jackson Labs' Baddi drug manufacturing licence restored after suspension

The unit's licence was cancelled in June after several women in Kota, Rajasthan, died allegedly due to spurious oxytocin injections supplied by the company's Punjab unit.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/agUXoKF
via IFTTT

Read More

Sun Pharma recalls eye drops in India after contamination scare

"Withdrawal of Product - Depopred2ML, Brinolar (BKC FREE), Brinzotim Eye Drops 5ML BKC FREE, Lotepred-5ML, Lotepred 1% Eye Drops SML, Lotepred LS 0.2%E/D5ML, Lotepred T, Nepalact OD Eye Drops 3ML, Nepalact-Z, Toba-F & Nepalact E/D 5ML."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/I9GNHCo
via IFTTT

Read More

TPG, Permira emerge as frontrunners in Rs 11,000 crore Cloudnine sale

TPG Capital and Permira are leading contenders for a significant minority stake in Cloudnine. The deal is expected to value India's largest maternity and pediatric hospital chain at approximately ₹11,000 crore. Binding bids are anticipated by mid-August after due diligence is complete. This transaction will facilitate True North's full exit after over a decade of investment. Cloudnine posted ₹2,000 crore revenue and ₹300 crore Ebitda in FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1wR8BM2
via IFTTT

Read More

Lupin launches generic Sugammadex injection in US

Lupin Limited announced the launch of its Sugammadex Injection in the United States. This follows approval from the US Food and Drug Administration for its abbreviated new drug application. The company's injection is claimed to be bioequivalent to Merck's Bridion Injection. It is indicated for reversing neuromuscular blockade in adult and pediatric surgical patients. The launch occurred on Friday, as per a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BKHaYWf
via IFTTT

Read More

As we look to the next decade, I hope in the future we can further grow in generics as we transition into drug innovation: Aman Mehta, MD, Torrent Pharmaceuticals

Torrent Pharma aims to become a top three Indian drug maker. The company is transitioning from generics to drug innovation for growth. Aman Mehta leads the firm with an ambitious future vision. He spearheaded a significant acquisition and focuses on weightloss drugs. Mehta emphasizes making the right strategic decisions for success.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Aa2ZNnG
via IFTTT

Read More

ChrysCapital acquires controlling 70.68% stake in Novartis' India listed unit in first majority pharma investment

ChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical landscape. Following this acquisition, the company is set to unveil a fresh name and corporate identity. Vikas Gupta has been appointed as the new CEO, with plans to create a competitive branded generics platform tailored for the Indian market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6yfHqpD
via IFTTT

Read More

ChrysCapital acquires controlling 70.68% stake in Novartis India in first majority pharma investment

ChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical landscape. Following this acquisition, the company is set to unveil a fresh name and corporate identity. Vikas Gupta has been appointed as the new CEO, with plans to create a competitive branded generics platform tailored for the Indian market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xmdxj2f
via IFTTT

Read More

FSSAI suspends licence of Dior Pharmaceuticals for violations at nutraceutical plant

The FSSAI has suspended Dior Pharmaceuticals' license due to serious violations. The nutraceutical factory operated with severely deficient good manufacturing practices. These deficiencies posed a significant risk to public health and safety. The company failed to ensure product safety, quality, and traceability. All operations must cease until compliance is fully established.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SpORKHG
via IFTTT

Read More

Gland Pharma gets USFDA nod for generic sugammadex injection

Gland Pharma secured USFDA approval for its sugammadex injection generic version. This drug reverses muscle relaxant effects used during surgical procedures. The approval covers two specific strengths of the single-dose vial product. This new generic is bioequivalent to Merck's BRIDION injection. The product had significant US sales in the past year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NQSndia
via IFTTT

Read More

Biocon gets Health Canada nod for Yesintek autoinjector pen

Biocon received Health Canada approval for its Yesintek autoinjector. This new format offers patients a convenient treatment option for psoriasis. The autoinjector is also indicated for psoriatic arthritis and Crohn's disease. This approval strengthens Biocon's immunology product portfolio in Canada. The company aims to increase patient access to affordable medicines globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/npFjlZO
via IFTTT

Read More

BDR Pharmaceuticals eyes controlling stake in Acme Formulation

PAG acquired a controlling stake in Acme Formulation for $145 million (?1,054 crore) through its PAG Asia III buyout fund in 2021. Founder and managing director Viral Shah retained a significant minority stake after the transaction and continued as managing director and CEO. PAG owns about 62% of the company, while Shah holds around 31%, with the balance is owned by other investors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JmlhNyz
via IFTTT

Read More

Andhra Pradesh teams up with AstraZeneca for next-gen cancer care model

Andhra Pradesh signed an MoU with AstraZeneca for an integrated precision oncology ecosystem. This initiative will integrate artificial intelligence and advanced genomics for cancer care. The collaboration aims to transform patient journeys from screening to follow-up. AstraZeneca will deploy AI-powered solutions for early lung cancer detection. An Integrated Genomic Solutions Centre will expand access to advanced cancer diagnostics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/icoxMLN
via IFTTT

Read More

Alembic Pharma gets USFDA approval for generic chronic constipation treatment tablets

Alembic Pharmaceuticals announced USFDA approval for its generic prucalopride tablets. The company received final approval for strengths of one and two milligrams. These tablets are indicated for treating chronic idiopathic constipation in adults. The approved drug is therapeutically equivalent to Takeda's Motegrity tablets. This market segment has an estimated size of one hundred million dollars.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wv8WLxY
via IFTTT

Read More

Sakar Healthcare posts Rs 10-crore profit in Q1

Sakar Healthcare announced a substantial net profit increase for the first quarter of 2026-27. The company's revenue from operations also saw a significant rise during the same period. Its oncology business remains a key strategic focus for the pharmaceutical manufacturer. Sakar Healthcare executed numerous oncology product contracts and has many discussions ongoing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZGICO6T
via IFTTT

Read More

Centre readies healthcare compliance overhaul to boost hospitals in tier-2, tier-3 cities

India plans major healthcare regulatory changes soon. These reforms aim to simplify licensing and reduce compliance burdens. The government will release a consultation paper within two months. This initiative seeks to encourage private investment in smaller cities. The goal is to improve healthcare access across the nation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CrMLy1Q
via IFTTT

Read More

PHC Mogla brings healthcare closer to Rajouri's remote villages

PHC Mogla now offers essential healthcare services locally. Residents previously traveled long distances for basic medical treatment. A portable X-ray machine aids emergency care for injured patients. Maternal healthcare has also seen significant local improvements. This facility has become a crucial lifeline for remote villagers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0d3FwBE
via IFTTT

Read More

US tariff proposal wake-up call for Indian pharma to diversify, innovate: Experts

US pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market reliance. There are warnings that ensuring patient access to affordable medications should remain paramount.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yst4R6k
via IFTTT

Read More

Sculpt, lift, glow: Face fitness is having a moment in India

Face fitness is emerging as a new category in India’s beauty and wellness market, blending facial massage, muscle stimulation and skincare into studio-led treatments. Premium brands and homegrown players are expanding as consumers seek non-invasive alternatives to aesthetic procedures, driven by growing interest in wellness, grooming and preventive beauty.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lzFpKvR
via IFTTT

Read More

Aster DM Quality Care to invest Rs 1,315 crore in Karnataka

Aster DM Quality Care will invest Rs 1,315 crore in Karnataka's healthcare infrastructure. This significant investment aims to strengthen the state's medical facilities and services. The company plans to develop new hospitals and expand existing ones in Bengaluru. These developments will enhance access to advanced tertiary and quaternary care. The commitment underscores Aster's long-term confidence in Karnataka's healthcare ecosystem.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gX19DFN
via IFTTT

Read More

AstraZeneca 'magic' faces rare test after trial failure, share slide

AstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern and impacted the company's share price. Investors now await results from two key oncology trials, SERENA-4 and AVANZAR. Success in these trials is crucial for maintaining confidence in AstraZeneca's research engine. The company aims for significant revenue growth by 2030 through new drug launches.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/deDbnmy
via IFTTT

Read More

FSSAI suspends Rehaan Healthcare licence over serious food safety violations

FSSAI has suspended Rehaan Healthcare’s licence after inspections revealed serious violations at its health supplements and nutraceutical manufacturing facility. The regulator found extremely unhygienic conditions, poor infrastructure, pest infestation, inadequate storage, and major food safety lapses, resulting in a very low compliance score of 12%. The company has been ordered to halt production until all deficiencies are rectified and verified by the competent authority, failing which legal action may follow.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u5PjhQJ
via IFTTT

Read More

Jackson Labs seeks restoration of its licence

The cancellation issued by the Punjab government followed reports that five women in Kota, Rajasthan, died after allegedly being administered an Oxytocin injection that upon testing found contained no active ingredient.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T9z30Rj
via IFTTT

Read More

India contributes one-third of global oral cancer burden; early detection key to survival, says oral cancer expert

India contends with a pressing oral cancer crisis, with thousands of new diagnoses and deaths emerging annually. The predominant factor behind this disease is the consumption of tobacco in diverse forms. Early detection via screening plays a critical role in managing and treating oral cancers successfully. It’s vital to monitor potentially malignant disorders closely and seek rapid medical assistance for ongoing oral health issues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8OHqfZa
via IFTTT

Read More

Trump's 200% generic drug tariff threat puts $9.7 billion Indian pharma exports at risk; industry says reshoring not practical

US President Trump's proposed tariffs on imported generic drugs will not immediately affect Indian drugmakers. Indian companies export significant generic medicines to the United States market. The proposed tariffs are set to begin in 2028, offering a two-year window. This lead time allows Indian firms to explore alternative export markets and adapt. American patients and insurers will likely face increased healthcare costs after tariffs are imposed.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WvB3al9
via IFTTT

Read More

Dr Reddy’s aims to resume semaglutide supply by November after API fix

Dr Reddy's expects to resume semaglutide supplies by November after resolving quality issues. The company identified the root cause and plans corrective measures by September. Financial results were impacted by a provision linked to the semaglutide active pharmaceutical ingredient. Despite disruptions, Dr Reddy's maintains its growth and profitability guidance for fiscal year 2027. The drugmaker anticipates supplying millions of semaglutide units this fiscal year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xl093uB
via IFTTT

Read More

Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% storm

Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufacturing and supply chain strategies. After this period, tariffs will escalate significantly, impacting export economics. Several Indian firms already have US manufacturing operations for flexibility. The next two years will shape how India serves its largest overseas pharmaceutical market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PsQ6hON
via IFTTT

Read More

Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%

For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the immediate impact on exports is likely to be limited, the proposed escalation to 100% and eventually 200% tariffs could significantly alter the economics of supplying generic medicines to the US if manufacturers do not establish a stronger local production footprint.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KYmzZXp
via IFTTT

Read More

ICMR licenses cancer, vaccine technologies to Emcure, Biological E

The Indian Council of Medical Research has licensed three new biomedical technologies. These innovations aim to advance cancer treatment and infectious disease protection. One drug candidate targets precancerous cervical cells, offering a safer treatment option. Two vaccine candidates will combat major bacterial gut infections. This initiative promotes government research into practical healthcare products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gzI0XQD
via IFTTT

Read More

Glenmark sees innovative products driving 70% revenue in 5-6 years: CMD Glenn Saldanha

Glenmark anticipates innovative products will drive nearly seventy percent of its revenue. This strategic shift moves the company away from its traditional generics-led model. The company is developing next-generation products targeting oncology and other complex diseases. Glenmark aims to become a global powerhouse in oncology within ten years. Artificial intelligence will significantly accelerate drug discovery and development processes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Jktyj1a
via IFTTT

Read More

Glenmark gets USFDA nod for expanded use of RYALTRIS nasal spray

Glenmark Pharmaceuticals announced US FDA approval for RYALTRIS nasal spray. This approval expands its use to children aged six to twelve years. The nasal spray treats symptoms of seasonal allergic rhinitis effectively. RYALTRIS combines antihistamine and corticosteroid in one formulation. This marks a significant step in expanding access to the treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yL6MSw9
via IFTTT

Read More

Japanese drugmaker Takeda's Qdenga becomes first dengue vaccine approved in India

India's drug regulator has approved Takeda's Qdenga dengue vaccine, the first of its kind. This vaccine is expected to become available in India during the first half of 2027. Qdenga offers protection against all four dengue virus serotypes for individuals aged four to sixty. The vaccine demonstrated significant efficacy in late-stage trials, reducing cases and hospitalisations. Takeda is also partnering with Biological E to boost global manufacturing capacity for Qdenga.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uXcade9
via IFTTT

Read More

Emcure Pharma gets CDSCO nod to market Poviztra for fatty liver treatment

Emcure Pharmaceuticals announced its brand Poviztra is now available for fatty liver treatment. This follows regulatory approval for treating metabolic dysfunction-associated steatohepatitis in adults. Poviztra contains innovator semaglutide manufactured in Europe by Novo Nordisk. The approval expands access to treatment for this progressive liver disease. This marks a significant milestone for patients with this serious condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/go3BxmL
via IFTTT

Read More

Takeda Biopharmaceuticals gets DCGI nod for dengue vaccine QDENGA

Takeda Biopharmaceuticals India has received market authorization for its dengue vaccine QDENGA. This vaccine is now approved for individuals aged four to sixty years old. QDENGA offers protection against all four dengue virus serotypes without prior testing. The vaccine has been approved in forty-three countries since its launch. India accounts for a significant portion of the global dengue burden.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eYgG18d
via IFTTT

Read More

Alcon to step up India investments; focus on innovation, training, says Senior Vice Prez Rajkumar Narayanan

Alcon is significantly increasing its investments in India's eye care market. The company sees India as a crucial emerging growth market for its future. Rising eye disorders among younger Indians are a key driver for Alcon's expansion. Alcon plans to enhance innovation and surgeon training programs across the nation. Future manufacturing in India is also being actively evaluated by the company.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Amds2LF
via IFTTT

Read More

Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bn

Alembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug, which is a generic equivalent of Lynparza. Alembic will distribute the product while NATCO Pharma will manufacture the tablets. The product addresses a significant market opportunity, estimated at USD 1.4 billion. Commercial launch depends on ongoing litigation, marking a regulatory milestone.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4tEAoYG
via IFTTT

Read More

Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killer

India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disease. The approval follows a committee recommendation for adults with moderate to advanced liver fibrosis. Wegovy, containing semaglutide, was previously approved for chronic weight management. This marks a significant expansion for the blockbuster obesity drug in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pCcdEbT
via IFTTT

Read More

Screens are straining young eyes, and Alcon sees India's opportunity

Alcon is increasing investments in India, recognizing its significant emerging market potential. The company focuses on innovation and surgeon training to address rising eye care needs. India's large population and growing myopia present substantial future growth opportunities. Alcon aims to enable advanced cataract care for millions by the year 2030. The global eye care leader is also evaluating future manufacturing possibilities within India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r3T1AC4
via IFTTT

Read More

Poly Medicure bets on new facilities, products to double international business: MD

The company's international business contributed ₹1,280.2 crore in FY26, accounting for nearly 68% of the company's total revenue of ₹1,875.3 crore. It expects the next phase of growth to be supported by two upcoming manufacturing facilities, a pipeline of more than 50 products, and a sharper focus on direct-market operations across key overseas geographies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VupHFhy
via IFTTT

Read More

Pharma exports to UK may rise up to 10% in FY27 as CETA takes effect

India's pharmaceutical exports to the UK are set to witness substantial growth thanks to the recently negotiated Comprehensive Economic and Trade Agreement. This groundbreaking agreement removes almost all tariffs on Indian drug products, enhancing the competitiveness of Indian generics and finished formulations. Preliminary data indicates promising trends in exports for this fiscal year, solidifying the UK's importance as a critical European market for India's pharmaceutical sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BSWdxhj
via IFTTT

Read More

India-UK FTA projected to boost Indian pharma exports by over 8% to $981 million in FY27: Pharmexcil

Indian pharmaceutical exports to the United Kingdom are projected to grow significantly. The India-UK Comprehensive Economic and Trade Agreement will eliminate tariffs on most products. This pact is expected to enhance the competitiveness of Indian generic medicines in the British market. The agreement also aims to secure supply chains and improve access to affordable medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sOz9NkP
via IFTTT

Read More

NITI Aayog roadmap targets USD 691 bn bioeconomy by 2035; Jitendra Singh says India ready to lead biotech revolution

India's bioeconomy can reach USD 691 billion by 2035, creating millions of high-value jobs. The nation aims to become a top global biotechnology power, driving future growth. A roadmap proposes six National BioMissions and a significant growth fund for development. Talent development, including engineering biology courses, is deemed critical for this ecosystem. This expansion will address national goals like health and food security.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jUBDlbs
via IFTTT

Read More

Kota kidney damage victims seek euthanasia or treatment in plea to President

Five women demand euthanasia after suffering kidney damage post C-section surgeries. They allege negligence and substandard drugs caused their critical health condition. Families face financial distress as husbands provide constant care for the ailing women. Repeated appeals to officials have yielded no resolution for their urgent medical needs. The petition seeks immediate kidney transplants and compensation or permission for dignified euthanasia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5GPctyg
via IFTTT

Read More

Warburg Pincus buys Mumbai’s pharma company Integrace in Rs 1,200 crore deal

In a landmark transaction, Warburg Pincus, a prominent US private equity firm, has purchased Integrace Private Limited for ₹1,200 crore. With this deal, True North and Temasek Holdings have decided to divest entirely from their stakes in the company. Rehan Khan, a seasoned leader in the industry, will take the helm as CEO, steering Integrace's focus on its celebrated orthopedic and gynecological brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bWKc1ym
via IFTTT

Read More

Jitendra Singh releases Rs 1,500 crore under third phase of Biomedical Research Career Programme

Union Minister Jitendra Singh released fifteen hundred crore rupees for the Biomedical Research Career Programme. This funding supports outstanding biomedical researchers and promotes collaborative research initiatives. The program, initiated in two thousand eight, has supported over five hundred researchers. It has also strengthened research across more than two hundred institutions nationwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JrUtK9b
via IFTTT

Read More

Warburg Pincus buys Mumbai’s pharma company Integrace in ₹1,200 crore deal

In a landmark transaction, Warburg Pincus, a prominent US private equity firm, has purchased Integrace Private Limited for ₹1,200 crore. With this deal, True North and Temasek Holdings have decided to divest entirely from their stakes in the company. Rehan Khan, a seasoned leader in the industry, will take the helm as CEO, steering Integrace's focus on its celebrated orthopedic and gynecological brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xiPgYI4
via IFTTT

Read More

Sun Pharma gets SAHPRA approval for generic semaglutide injection in South Africa for type 2 diabetes

South Africa's regulator approved Sun Pharma's generic semaglutide injection for diabetes. This approval allows marketing to supplement diet and exercise for adults. The company plans to launch the product soon in injectable pens. South Africa is the second market after India for this approval. This reflects Sun Pharma's commitment to improving access to generics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S7kuYoN
via IFTTT

Read More

OneSource Specialty Pharma partners with Formycon AG to manufacture biosimilars

OneSource Specialty Pharma has announced a manufacturing partnership for biosimilars with Formycon AG. This collaboration will see OneSource providing integrated manufacturing capabilities for biosimilars. The partnership aims to expand access to high-quality, affordable biologics for patients globally. Formycon AG CEO stated this strengthens their supply capabilities with a quality-focused partner. Both companies aim to broaden sustainable global access to life-changing biosimilar therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EtkJz94
via IFTTT

Read More

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

The US FDA approved an at-home starting dose for Eisai and Biogen's Alzheimer's drug. This new subcutaneous formulation allows patients to self-administer injections, improving access. Previously, patients received intravenous infusions, typically at clinics, for initial treatment. This approval differentiates Leqembi from competitor Kisunla's infusion-only requirement. The drug targets amyloid beta plaques in the brains of Alzheimer's patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oj2OFg0
via IFTTT

Read More

Warburg, Bain, CVC among PE firms in talks to buy into Agappe Diagnostics

Several global private equity firms are exploring a significant stake purchase in Agappe Diagnostics. This potential deal involves both existing investor sales and new capital infusion. The transaction is expected to value the Kochi-based in-vitro diagnostics firm at over three thousand crore rupees. Agappe Diagnostics develops and manufactures diagnostic reagents and equipment for global markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GAwaOnq
via IFTTT

Read More

Emcure buys remaining 12.05% in Gennova to take full control

Emcure Pharma is acquiring the remaining stake in Gennova Biopharmaceuticals. This move simplifies ownership and sharpens strategic focus for the subsidiary. Gennova will now be led by Samit Mehta for its next growth phase. The company will continue leveraging its biomanufacturing platforms for new products. Gennova's former CEO Sanjay Singh has divested its mRNA business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VYAtfO9
via IFTTT

Read More

First vaccine for Bundibugyo Ebola hits human trials in Oxford study

Oxford's Ebola vaccine candidate has entered Phase 1 clinical trials for safety evaluation. The ChAdOx1 BDBV vaccine uses a platform similar to the Covid-19 vaccine. Serum Institute of India manufactured approximately 620,000 doses for potential future use. This initiative builds on a strategic partnership with CEPI and the University of Oxford. Late-stage trials will follow if Phase 1 results prove successful.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ykevW63
via IFTTT

Read More

Schedule H1 explained: Why did India tighten its prescription rules for high-alcohol medicines?

Schedule H1 Explained: High-alcohol oral medicines now require a doctor's prescription under Schedule H1. This stricter classification mandates detailed sales records for pharmacies. The government aims to prevent misuse and diversion of these potent preparations. Previously exempt alcohol-based tonics face new licensing and prescription rules. Patients will need valid prescriptions for these medicines moving forward.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y318qeg
via IFTTT

Read More

Pharma body renews push for data protection

Leading pharmaceutical companies seek Regulatory Data Protection to boost research investments. Public health groups and local makers oppose this, fearing extended monopolies and delayed generics. The Organization of Pharmaceutical Producers of India argues it benefits indigenous drug makers too. China has already implemented similar clauses, seeing significant research deal growth. India's regulatory alignment with global practices could attract discovery research investments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RGLQobI
via IFTTT

Read More

Antibiotic resistance emerging as major threat to surgical care: Experts

Antimicrobial resistance now challenges routine surgical procedures and increases infection risks. Surgeons warn that losing effective antibiotics undermines decades of progress in safe surgery. Hospitals are adopting stricter antibiotic stewardship and infection prevention measures. Multidrug-resistant organisms pose a significant challenge to treating post-operative infections effectively. Preserving antibiotic effectiveness is a shared responsibility for future generations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1wU9h0H
via IFTTT

Read More

Maharashtra FDA bars sale of two Cadila drugs over branding concerns

Maharashtra FDA has seized Cadila Pharmaceuticals drug stock worth Rs 2.45 crore. The action was taken due to similar branding on different active ingredients. Officials barred sales of Aciloc 150 Plus and Aciloc 300 Plus medicines. This move aims to prevent medication errors and safeguard public health. Further investigation and legal action are currently underway.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JnbCdmg
via IFTTT

Read More

Medicines with over 12% alcohol can no longer be sold without prescription: Govt

In a new regulatory change, medications with alcohol content exceeding twelve percent will require a prescription from a doctor. This decision treats these products like standard prescription drugs, compelling manufacturers to obtain the necessary licenses. Furthermore, pharmacies are now tasked with rigorous record-keeping to mitigate potential abuse and ensure that genuine medical use is preserved under enhanced scrutiny.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KFcNM9Q
via IFTTT

Read More

Dr Reddy’s pauses weight loss drug on quality fears

Dr Reddy's Laboratories will halt semaglutide injection supplies until at least October. Unspecified impurities were identified during the active pharmaceutical ingredient manufacturing scale-up. The company assures that already supplied market products remain safe for patient use. Torrent Pharmaceuticals and USV Ltd are recalling some semaglutide batches sourced from Dr Reddy's. Commercial supplies are expected to resume after the issue is resolved and validation is complete.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dwmf6Hl
via IFTTT

Read More

GA-Renova & CCA in race to buy American oncology: Siemens Healthineers looking to exit non-core business for Rs 1,500 crore

Two prominent players are in the running to purchase American Oncology Institute from Siemens Healthineers. One of the potential buyers is General Atlantic in collaboration with Renova Hospitals, while the other contender is Raj Mantena's Cancer Centers of America. Siemens Healthineers initially acquired this cancer network as part of a larger strategic agreement. The completion of the sale is anticipated by mid-August.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SNcbioP
via IFTTT

Read More

Dr Reddy's flags quality issue in semaglutide batches, delays commercial supplies

Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batches associated with an active ingredient concern. The firm is actively investigating to identify the source of the problem and is implementing corrective strategies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0z2tmvd
via IFTTT

Read More

Novo Nordisk readies once-a-week insulin shot for Indian market

Novo Nordisk is set to introduce Awiqli, an innovative once-weekly insulin, in India shortly. This remarkable treatment drastically cuts down the number of insulin injections from 365 annually to only 52. Awiqli could redefine the approach to diabetes management, offering promising cost savings compared to existing therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ChAb7oH
via IFTTT

Read More

Cultural sensitivity, communication key to strengthening India's medical tourism appeal: IIM experts

Experts highlight cultural sensitivity and communication's importance for international medical tourists. Effective expectation management and communication enhance patient experiences in Indian hospitals. India is a leading medical tourism destination due to advanced healthcare and affordable costs. Hospitals should invest in intercultural communication training for professionals. Bridging cultural gaps improves patient satisfaction and India's market competitiveness.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OCSImb8
via IFTTT

Read More

Navi Mumbai Airport notified as port for import of drugs under Drugs Rules

Navi Mumbai Airport has been designated as a port for drug imports, a decision that boosts the pharmaceutical supply chain and simplifies trade activities. Following the amendment to Drugs Rules, 1945, the total number of notified ports has increased to 42. This initiative is aimed at facilitating efficient movement of pharmaceutical goods and enhancing regulatory oversight, showcasing the government's dedication to improving trade dynamics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AWFJEtN
via IFTTT

Read More

Regulator seeks views to curb similar sounding drug brands

The Central Drugs Standard Control Organisation in India is inviting public contributions concerning new regulations aimed at curbing the sale of various medications under similar brand names, which can mislead both patients and pharmacists about their contents. As part of this initiative, the drug regulator has released a notice for stakeholder observations, with a deadline for comments set for July 17 to ensure improved safety and trust among patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nTO3oJP
via IFTTT

Read More

India's wellness industry poised for growth amid focus on preventive healthcare, rising income: EBG Group chief

India's wellness market, valued at over $150 billion, is set for growth fueled by rising health consciousness and disposable incomes. EBG Group is launching Carlton Wellness India, an integrated ecosystem blending traditional Indian healing with modern hospitality. This platform will offer diverse wellness experiences, from city centers to retreats, emphasizing preventive care and holistic wellbeing for everyday life.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WPFLkpU
via IFTTT

Read More

Gene therapy firm Immuneel ties up with Arogya Finance to offer Rs 25 lakh zero-cost EMI for cancer treatment

Immuneel Therapeutics collaborates with Arogya Finance to unveil a zero-cost EMI scheme for advanced cancer treatments, providing support of up to Rs 25 lakh. This effort is a segment of Immuneel's Saksham Patient Access Program, letting eligible patients benefit from interest-free installments for as long as 12 months, thereby reducing financial pressures and facilitating prompt access to essential therapies for those in need.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9GLTgKS
via IFTTT

Read More

Glenmark launches generic Olanzapine injection in US

Glenmark Pharmaceuticals has launched a generic version of Olanzapine injection in the United States, offering a treatment for schizophrenia and bipolar disorder. This move by its US arm, Glenmark Pharmaceuticals Inc., introduces a bioequivalent alternative to Zyprexa intramuscular injection. The company aims to expand its injectable offerings and bolster its presence in the institutional market, targeting a segment with significant annual sales.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cZKjp6i
via IFTTT

Read More